Moreover, T cell immunoglobulin and the ITIM domain (TIGIT) is a coinhibitory transmembrane glycoprotein expressed on CD8+ cytotoxic T cells, CD4+ Th cells and FOXP3+ T-regs, which has a critical role in regulating exhausted CD8+ T cell responses in tumours [127,128] Li and coworkers found a variable proportion of TIGIT+/PD-1+ in cHL samples and this combination represents an attractive candidate for coblockade with the PD-1 pathway inhibitor [128]. The gene discussed is CD8A; the disease is neoplasm.